Ten‐year longitudinal analysis of hydroxyurea implementation in a pediatric sickle cell program
Authors:
- 2 September 2022
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 109 (5) , 465-473
Abstract
Hydroxyurea (HU) has proven benefit in sickle cell anemia (SCA), but HU is still underutilized. The Pediatric Sickle Cell Program of Northern Virginia prescribes HU regardless of symptoms to all SCA patients age >= 9 months and prospectively tracks outcomes. HU is dosed to maximum tolerated dosing (MTD), targeting 30% Hgb F. Longitudinal data from 2009 to 2019 encompassing 1222 HU-eligible and 950 HU-exposure patient-years were analyzed in 2-year intervals for hemoglobin (Hgb), fetal hemoglobin (Hgb F), hospitalizations, transfusions, and treat-and-release ED visits. Comparing HU-eligible patients in the interval prior to HU implementation (2009-2011) to the last interval analyzed after HU implementation (2017-2019), HU usage increased from 33% to 93%, average Hgb increased from 8.3 +/- 0.98 to 9.8 +/- 1.3 g/dl (p < .0001), average Hgb F rose from 13 +/- 8.7% to 26 +/- 9.9% (p < .0001), hospitalizations decreased from 0.71 (95% CI 0.54-0.91) to 0.2 (95% CI 0.13-0.28) admissions/person-year, sporadic transfusions decreased from 0.4 (95% CI 0.27-0.55) to 0.05 (95% CI 0.02-0.12) transfusions/person-year. Treat-and-release ED visit rates remained unchanged, varying between 0.49 (95% CI 0.36-0.64) and 0.64 (95% CI 0.48-0.83) visits/person-year. By the last interval, 72% of patients had Hgb >= 9 g/dl, 42% had Hgb F >= 30%, 79% experienced no hospitalizations, and 94% received no transfusions. Uniform HU prescription for SCA patients with close monitoring to achieve high Hgb F resulted in significant improvements in laboratory and clinical outcomes within 2 years, which continued to improve over the next 6 years. Rigorous HU implementation in a pediatric sickle cell population is feasible, effective, and sustainable.Keywords
All Related Versions
This publication has 22 references indexed in Scilit:
- Barriers to hydroxyurea adherence and health‐related quality of life in adolescents and young adults with sickle cell diseaseEuropean Journal of Haematology, 2017
- Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population‐based cohortAmerican Journal of Hematology, 2016
- Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital usePediatric Blood & Cancer, 2016
- Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York StateAmerican Journal of Preventive Medicine, 2016
- Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatmentPediatric Blood & Cancer, 2015
- Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefitBritish Journal of Haematology, 2014
- Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell ProgramPLOS ONE, 2013
- The effect of hydroxcarbamide therapy on survival of children with sickle cell diseaseBritish Journal of Haematology, 2013
- Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilizationAmerican Journal of Hematology, 2010
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010